Breaking News

Patheon Board Recommends Rejecting JLL Offer

Patheon's board of directors has recommended that shareholders reject JLL's recent $2 per share tender offer to take the company private.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Patheon‘s board of directors has recommended that shareholders reject JLL Partners‘ recent $2 per share tender offer to take the company private. The board, based on a unanimous recommendation of the special committee of independent directors, concluded that the offer undervalued Patheon’s shares. JLL has three nominees and the board; all declared conflicts of interest and did not vote on the recommendation. Patheon chief executive officer Wes Wheeler also abstained from voting...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters